AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05168345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Course and web information
Description: The interventional phase of the study will be conducted on IBD patients only. Patients will undergo two interventional periods which will include:~1. Self-selected information from the internet - patients will be asked to independently search the web for information regarding the categories of information which are discussed in the online course.~2. An online, interactive IBD course. Lectures will be passed by the multidisciplinary team of the IBD Center which includes IBD gastroenterologists, an IBD nurse, an IBD dietitian, and a social worker.
Study NCT02876653 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography , blood collection, bone densitometry and Functional respiratory explorations
Description: Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers
Study NCT03937089 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection from medical file
Study NCT01331278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty with Custom Cutting Blocks
Description: Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
Study NCT01331278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty via Computer Assisted Surgery
Description: Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
Study NCT03185143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Acetaminophen Combination
Description: Treat a single Qualified Migraine attack.
Study NCT03185143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 100 mg
Description: One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
Study NCT03185143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
Study NCT01307306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin R
Description: Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
Study NCT01307306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
Study NCT03720249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation of compound nutrients
Description: Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.
Study NCT03720249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.
Study NCT00433706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control position by 3DOBI before the fraction
Study NCT00433706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard imaging
Study NCT00695864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron and Placebo crossover
Study NCT00994851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENNA+CASSIA
Description: Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
Study NCT00994851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
Study NCT04641052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: The music type will be chosen by the patients and researchers will not have any influence on their choices.
Study NCT03111368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided fine needle aspiration
Description: pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
Study NCT03890653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance-Based Financing
Description: Incentive-based payments
Study NCT03890653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decentralized Facility Financing
Description: Financing not linked to service delivery.
Study NCT01336842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat, Cisplatin, Pemetrexed
Description: Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1.
Study NCT01754571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Behavior therapy, including Relaxation, cognitive rebuilding.
Study NCT01894022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Description: Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
Study NCT03760679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask Supreme evaluation
Description: Device: Laryngeal mask Supreme evaluation
Study NCT03760679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel evaluation
Description: Device: i-gel evaluation
Study NCT04314011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells（HUC-MSCs）
Description: Human umbilical cord mesenchymal stem cells（HUC-MSCs）
Study NCT04314011 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02486965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermode (TSA-II model)
Description: thermal stimulation with test thermode
Study NCT02486965 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adapted Physical Activity
Study NCT02486965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Study NCT02486965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Study NCT02651220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo® Forte Gel
Description: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
Study NCT02651220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl Peroxide Gel
Description: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
Study NCT02651220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: vehicle used as placebo
Study NCT01272765 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01272765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHBG-10
Description: 500 mg IHBG-10
Study NCT03327194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHEAR Audio Processor
Description: ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark.
Study NCT00794885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril/folic acid
Description: Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
Study NCT00794885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril maleate
Description: Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
Study NCT01984996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom ProFlor Inguinal Hernia Implant
Study NCT03363880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trauma treatment team
Description: Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.
Study NCT03363880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic experimental settings
Description: Establishing the trauma management system without a trauma treatment team.
Study NCT03492801 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03492801 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04038567 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile mindfulness-based training
Description: The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
Study NCT02772185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus
Study NCT02772185 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
Study NCT02772185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
Study NCT02772185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real CT
Description: Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).
Study NCT02772185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: placebo CT
Description: Videos (short films) will be presented during the neurostimulation
Study NCT02772185 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo CT
Description: Videos (short films) will be presented during the neurostimulation
Study NCT02760316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 10 mg
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Study NCT02760316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 20 mg
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Study NCT02760316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 40 mg
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Study NCT02760316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 80 mg
Description: Oral suspension Multiple doses 5 days of treatment Once daily
Study NCT02760316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 20 mg
Description: Oral Multiple doses 5 days of treatment Once daily
Study NCT02760316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 125 mg
Description: Oral Multiple doses 5 days of treatment Once daily
Study NCT02760316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 155 mg
Description: Oral Multiple doses 5 days of treatment Once daily
Study NCT02760316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 5 mg
Description: Oral Multiple doses 5 days of treatment Once daily
Study NCT04311983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Quitline
Description: Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back).
Study NCT04311983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Quitline
Description: Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back).
Study NCT04311983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free Home
Description: The intervention guides participants though a 5-step process: (1) deciding to create a smoke-free home; (2) talking about it with household members; (3) setting a date for the home to become smoke-free; (4) making the home smoke-free; and (5) keeping the home smoke-free. Progress from one step to the next is facilitated over a 6-week period by three mailings sent to participants' homes and one telephone counseling call delivered by a trained smoke free homes coach.
Study NCT04148885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT04148885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Patients secondly receive carboplatin AUC=5 (iv, 30 minutes) on days 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study NCT02558543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stromal Vascular fraction
Study NCT02558543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer lactate
Study NCT01623011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Sub-acromial Decompression Surgery
Description: The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
Study NCT02631889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcollation technology
Description: The use transcollation technology for dissection during lung surgery
Study NCT02631889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional electrocautery
Description: The use of traditional Electrocautery for dissection during Lung Surgery
Study NCT01623011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Arthroscopy
Description: This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
Study NCT03888066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
Study NCT03888066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
Study NCT01047514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Online Workshop
Description: 6 week, online, small group self-management workshop
Study NCT03971474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT03971474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT03971474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03971474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03971474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV
Study NCT03971474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT03971474 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV
Study NCT01623011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Monitoring with Specialist Reassessment
Description: Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
Study NCT02760316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 40 mg
Description: Oral Multiple doses 5 days of treatment Once daily
Study NCT02776254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: START
Description: Point of care testing for rapid ART initiation
Study NCT02776254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAG
Description: Community Adherence Group
Study NCT04155372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Different Fluid Ingestion Rate
Description: The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.
Study NCT01851694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
Study NCT01851694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP
Description: Each subject in this arm will receive GIP infusion and placebo during a GPA test.
Study NCT04499898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol
Study NCT04499898 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic band ligation
Description: Endoscopic band ligation
Study NCT04401943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online fatigue intervention
Description: on line teleconferencing fatigue intervention for 6 weeks on causes of fatigue, ways to protect joint and save energy, ways to manage stress, pain, good eating habits, and exercise.
Study NCT03236779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.